Answers are grounded in this paper and cite their sources.
Key Points In a cross-sectional study, sodium-glucose cotransporter 2 inhibitors were associated with a significant increase in urine volume and urine citrate. Glucagon-like peptide-1 receptor agonists were not associated with any significant changes in 24-hour urine parameters that affect stone formation. Background Emerging data suggest sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) may lower stone risk. Methods We characterized 24-hour urine parameters among patients with kidney stone disease receiving these agents using Medicare claims from beneficiaries with urine collections processed by a central laboratory between January 2010 and December 2019. We identified a cross-sectional cohort with diabetes and a prescription fill for SGLT2is or GLP-1RAs within the 6 months preceding their urine collection and matched controls. We additionally identified a subset of patients who performed two collections and had a prescription fill for SGLT2is or GLP-1RAs before the second collection, but not the first. We compared across 24-hour urinary parameters in both cohorts and adjusted for multiple comparisons. Results The cross-sectional cohort included 124 patients with a prescription fill for SGLT2is (and 620 matched controls) and 349 patients with a prescription fill for GLP-1RAs (and 349 matched controls). Compared with controls, patients on SGLT2is had a higher mean urine citrate (838 versus 636 mg; P < 0.01) and volume (2.4 versus 2.0 L; P < 0.01) with improved calcium phosphate supersaturation ( P < 0.01). Lower urine pH and higher sulfate and uric acid were observed in the SGLT2i group ( P < 0.01 for each). There were no significant differences in urine parameters with GLP-1RA. In the longitudinal analyses of SGLT2is (59 patients) and GLP-1RAs (154 patients), there were no significant differences in urinary parameters. Conclusions SGLT2is were associated with higher urine volume and citrate in a cross-sectional cohort. GLP-1RAs were not associated with changes that would reduce stone risk.
No takes yet. Share an insight, caveat, or question.
Schaub et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: